Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
Saved in:
| Title: | Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial. |
|---|---|
| Authors: | Huang, Tao1 (AUTHOR), Hu, Qianqian2 (AUTHOR), Zhou, Xiang2 (AUTHOR), Yang, Huaiyu2 (AUTHOR), Xia, Wei1 (AUTHOR), Cao, Feng3 (AUTHOR), Deng, Minglu2 (AUTHOR), Teng, Xiaoxue2 (AUTHOR), Ding, Fan2 (AUTHOR), Zhong, Zaixin2 (AUTHOR), Gao, Lidong1 (AUTHOR) gldlj@hotmail.com, Sun, Jiufeng4 (AUTHOR) sunjiuf@163.com, Gong, Lihui2 (AUTHOR) gonglihui@zhifeishengwu.com |
| Source: | BMC Infectious Diseases. 4/19/2024, Vol. 24 Issue 1, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14712334 |
|---|---|
| DOI: | 10.1186/s12879-024-09293-1 |
